Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Genus (GNS) Share News

LONDON BRIEFING: GSK wins EU nod for RSV shot; Spire in early talks

26th Jan 2026 07:59

(Alliance News) - GSK wins EU approval to expand use of its RSV vaccine Arexvy to all adults over 18, while Grainger unveils plans for a 195-home West London development, and Impax Environmental Markets outlines its tender offer plan amid continued pressure from activist investor Saba. Read More

IN BRIEF: Genus says PRRS resistant pig gene edit approved in Canada

26th Jan 2026 06:57

Genus PLC - Basingstoke, England-based animal biotechnology and genetics - Says government approves the use of its gene edit for pigs, which provides resistance to a global disease. Porcine reproductive and respiratory syndrome causes suffering and premature death to pigs, with Genus noting a study that estimated the cost of PRRS at USD1.2 billion per year in the US alone. The approval of the PRRS resistant pig programme follows years of work with multiple Canadian regulators, Genus says, and is an important step toward commercialisation in North America. Genus is seeking approval for the PRP gene edit in key North American export markets such as Mexico and Japan, as well as in China. Read More

FTSE 100 Latest

Value10,223.54

Change51.78